Similar articles

• A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.

  Alty JE, Monaghan TM, Bamford JM. Alty JE, et al. Clin Neurol Neurosurg. 2007 Apr;109(3):279-81. doi: 10.1016/j.clineuro.2006.11.002. Epub 2006 Dec 14. Clin Neurol Neurosurg. 2007. PMID: 17174468
• Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders.

  Calamia KT. Calamia KT. Adv Exp Med Biol. 2003;528:545-9. doi: 10.1007/0-306-48382-3_110. Adv Exp Med Biol. 2003. PMID: 12918761 Review. No abstract available.
• [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].

  van Laar JA, Jamnitski A, Baarsma GS, van Daele PL, van Hagen PM. van Laar JA, et al. Ned Tijdschr Geneeskd. 2006 Apr 1;150(13):705-9. Ned Tijdschr Geneeskd. 2006. PMID: 16623340 Dutch.
• [Adamantiades-Behcet's disease].

  Krause L. Krause L. Ophthalmologe. 2005 Apr;102(4):329-34. doi: 10.1007/s00347-004-1166-2. Ophthalmologe. 2005. PMID: 15668761 Review. German.
• Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.

  Ariyachaipanich A, Berkelhammer C, Nicola H. Ariyachaipanich A, et al. Inflamm Bowel Dis. 2009 Dec;15(12):1769-71. doi: 10.1002/ibd.20869. Epub 2009 Jan 28. Inflamm Bowel Dis. 2009. PMID: 19177427 No abstract available.